FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

Sirakoss Receives CE Mark for Bone Graft Substitute

Feb. 1, 2019
A A

Sirakoss’ Osteo3 nanosynthetic bone graft substitute gained the CE Mark, offering surgeons another way to repair bone fractures.

The bone graft substitute is used for fixing congenital or degenerative conditions, such as curvature of the spine, by fusing bones together during surgery. It can also be used after a bone fails to heal following a traumatic injury.

The Osteo3, which is comprised of an inorganic matrix that is reabsorbed completely into the bone, has a surface chemistry that promotes rapid and complete bone regeneration.

View today's stories